Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid?
Manuscript Number:
16-0302R2
Author(s):
Anna Barnes, Jamshed Bomanji, John Dickson, Nick C. Fox, Irfan Kayani, Michael P. Lunn, Catherine J. Mummery, Ross W. Paterson, Martin N. Rossor, Jonathan M. Schott, Jason D. Warren, Philip S.J. Weston, Henrik Zetterberg
Disclosures
Anna Barnes
Nothing to Disclose
Jamshed Bomanji
Nothing to Disclose
John Dickson
Nothing to Disclose
Nick C. Fox
Consulting Fees:
I provide consultancy services to Eli Lilly, Novartis, Sanofi, Roche, GSK, and Biogen - all payments were to UCL Institute of Neurology.
Irfan Kayani
Nothing to Disclose
Michael P. Lunn
Consulting Fees:
I have received ad hoc consulting fees from CSL Behring, Baxalta, Novartis and Grifols for single advisory board attendances in relation to products used to treat inflammatory neuropathies
Catherine J. Mummery
Nothing to Disclose
Ross W. Paterson
Nothing to Disclose
Martin N. Rossor
Consulting Fees:
Membership of SMC for Servier AD trial
Fees paid to university
Jonathan M. Schott
Consulting Fees:
I have consulted for Roche Pharmaceuticals and Eli Lilly.
Lecture Fees:
I have received lecture fees from Eli Lilly
Patents/Royalties
I serve on a Data Safety Monitoring Committee for Axon Neuroscience SE